

Replimune's oncolytic immunotherapy RP1 is designed to treat certain cancers



What is oncolytic immunotherapy?

Oncolytic immunotherapy (OI) is a cancer treatment that uses a type of virus to break down tumors—but not normal tissue in the body—and is intended to induce an immune response against the patient's cancer. OI viruses are uniquely targeted to tumors and may make it easier to kill tumors when combined with other anticancer drugs, including immunotherapies.

The goal of immunotherapy is to use the body's immune system to fight cancer



Vusolimogene oderparepvec (RP1) is an experimental treatment that is currently available through clinical trials only. How do I know if the treatment is right for me?

- You may be eligible to join the IGNYTE or CERPASS clinical trials if you have been diagnosed with
 - Certain skin cancers:
 - ◊ Melanoma, and have been previously treated with certain immunotherapies
 - ◊ Cutaneous squamous cell carcinoma (CSCC)
 - ◊ Basal cell carcinoma (BCC)
 - ◊ Merkel cell carcinoma (MCC)
 - Other types of cancers:
 - ◊ Non-small cell lung cancer (NSCLC)
 - ◊ Cancers considered to have high microsatellite instability (MSI-H)
 - ◊ Cancers deficient in mismatch repair (dMMR)



Every cancer is unique. Your doctor or treatment center can guide you through the best treatment options, including new treatments.